Nycomed announces marketing collaboration for Easyhaler

Nycomed is set to co-market Easyhaler with Orion Corporation in Europe and the Middle East & North Africa region (MENA).

The companies have revealed that the asthma and chronic obstructive pulmonary disease (COPD) treatment will be commercialised under their own brands alongside the Easyhaler name.

Guido Oelkers, executive vice-president of commercial operations at Nycomed, suggested the treatment will significantly enhance the firm's respiratory portfolio.

"We are very pleased to have signed this collaboration agreement with Orion. We see great potential in these high quality Easyhaler products in major European countries and the MENA region," he added.

In response, senior vice-president of Orion's proprietary products division Dr Liisa Hurme said she is excited to have such a strong partner for its asthma and COPD work.

Nycomed is in the process of being acquired by Takeda Pharmaceutical, with Asia's largest pharmaceutical firm due to pay about 9.6 billion euros (8.3 billion pounds) on a cash-free, debt-free basis.